摘要
目的:探讨桂枝茯苓胶囊与屈螺酮炔雌醇联合治疗子宫内膜异位症对患者子宫内膜厚度与血流的影响。方法:选择2017年1月—2019年1月我院收治的180例子宫内膜异位症患者作为研究对象,根据随机数字表法分为对照组与观察组,各90例。对照组给予屈螺酮炔雌醇(1片,qd)治疗,观察组在对照组基础上给予桂枝茯苓胶囊(0.93 g,tid)治疗。比较两组卵巢异位囊肿直径、血清CA125、安全性及治疗效果。结果:治疗后,观察组治疗总有效率较对照组高,差异有统计学意义(P <0.05);治疗后,观察组卵巢异位囊肿直径、血清CA125及不良反应发生率均低于对照组,差异有统计学意义(P <0.05)。结论:桂枝茯苓胶囊与屈螺酮炔雌醇联合治疗子宫内膜异位症的疗效理想,能有效缩小卵巢异位囊肿,降低血清CA125水平,且具有较高的安全性,值得临床推广应用。
Objective:To investigate the effect of guizhi fuling capsules combined with drospirenone ethinylestradiol on endometrial thickness and blood?ow in patients with endometriosis.Methods:180 patients with endometriosis admitted to our hospital from January 2017 to January 2019 were selected as subjects investigated,and they were randomly divided into a control group and an observation group,90 cases each.The patients in the control group were treated with drospirenone ethinylestradiol(1 tablet,qd),and the patients in the observation group were treated with guizhi fuling capsules(0.93 g,tid)on the basis of the control group.The diameter of ovarian ectopic cysts,serum CA125,safety and therapeutic effect were compared between the two groups.Results:After treatment,the total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the diameter of ovarian ectopic cysts,serum CA125 and the incidence of adverse reactions in the observation group were lower than those in the control group,and the differences were statistically signi?cant(P<0.05).Conclusion:Guizhi fuling capsules combined with drospirenone ethinylestradiol are effective in the treatment of endometriosis,which can effectively reduce ovarian ectopic cysts and reduce serum CA125 level,and have high safety,and are worthy of clinical promotion and application.
作者
陈茜
Chen Qian(Department of Gynecology and Obstetrics,Yongcheng Maternal and Child Health Hospital,Yongcheng Henan 476600,China)
出处
《中国合理用药探索》
CAS
2019年第5期79-81,共3页
Chinese Journal of Rational Drug Use
